← Product Code [HQC](/submissions/OP/subpart-e%E2%80%94surgical-devices/HQC) · K122829

# LENSAR LASER SYSTEM - FS 3D FOR CORNEAL INCISIONS (K122829)

_Lensar, Inc. · HQC · Dec 3, 2012 · Ophthalmic · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/HQC/K122829

## Device Facts

- **Applicant:** Lensar, Inc.
- **Product Code:** [HQC](/submissions/OP/subpart-e%E2%80%94surgical-devices/HQC.md)
- **Decision Date:** Dec 3, 2012
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 886.4670
- **Device Class:** Class 2
- **Review Panel:** Ophthalmic
- **Attributes:** Therapeutic

## Intended Use

The LensAR Laser System - fs 3D (LLS-fs 3D) is intended for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, laser phacofragmentation, and the creation of single-planc and multi-plane cuts/incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure.

## Device Story

Ophthalmic surgical laser system; utilizes femtosecond laser pulses for anterior capsulotomy, phacofragmentation, and corneal incisions. Input: biometric system data (3D model of eye optical surfaces, including peripheral cornea). Operation: laser beam guidance system delivers pulses to target tissue; biometric system performs ray tracing to guide incision placement. Output: precise laser-cut incisions and lens fragmentation. Used in clinical settings by surgeons. Benefits: improved consistency of wound geometry and incision length compared to manual methods; reduced endothelial cell loss in specific incision geometries. System includes patient interface device (PID) and moveable optical head for docking.

## Clinical Evidence

Bench testing only. Evaluated accuracy/reproducibility of laser vs. manual corneal incisions; laser incisions showed statistically significantly closer mean length to target and lower variance in geometry. Ex vivo porcine eye study compared endothelial cell loss; laser method showed statistically smaller percentage losses for specific incision geometries. Seal integrity testing showed no difference in leakage susceptibility between laser and manual methods. Hazard analysis confirmed ocular safety.

## Technological Characteristics

Femtosecond laser system; pulse energy control/monitoring; biometric system with scanning diode light source; LED eye illumination. Patient interface device (PID) with controlled force docking. Software-driven custom shot pattern generation. Connectivity: standalone system. Sterilization: not specified.

## Regulatory Identification

A phacofragmentation system is an AC-powered device with a fragmenting needle intended for use in cataract surgery to disrupt a cataract with ultrasound and extract the cataract.

## Predicate Devices

- LensAR Laser System - fs 3D ([K120214](/device/K120214.md))
- LenSx 550 Laser System ([K101626](/device/K101626.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

Section 6: 510(K) Summary

## 510(K) SUMMARY

DEC 3 2012

K12282

This 510(k) summary is being submitted in accordance with the requirements of 21 CFR 807.92(a).

#### SUBMITTER'S NAME, ADDRESS, TELEPHONE NUMBER, CONTACT PERSON, AND DATE SUMMARY PREPARED

|  | a. Applicant: | LensAR, Inc.                    |
|--|---------------|---------------------------------|
|  |               | 2800 Discovery Drive, Suite 100 |
|  |               | Orlando, FL 32826               |
|  |               | Tel: (888) 536-7271             |
|  |               | Fax: (407) 386-7228             |

- S.K. McGarvey b. Contact Person: Regulatory Consultant skmcgg@aol.com Cell: (702) 524-3701 Fax: (407) 386-7228
### DATE SUMMARY PREPARED: September 14, 2012

# NAME OF DEVICE, INCLUDING TRADE NAME AND CLASSIFICATION NAME

| a. Trade/Proprietary Name: | LensAR Laser System - fs 3D (LLS-fs 3D)     |
|----------------------------|---------------------------------------------|
| b. Common/Usual Name:      | LensAR Laser System - fs 3D (LLS-fs 3D)     |
| c. Classification Name:    | Ophthalmic Laser, Phacofragmentation System |
| d. Classification Code(s): | 21 CFR 886.4390 OOF: 21 CFR 886.4670 UOC    |

#### PREDICATE DEVICES

| 510(K) # | TRADE NAME                  | MANUFACTURER               |
|----------|-----------------------------|----------------------------|
| K120214  | LensAR Laser System - fs 3D | LensAR, Inc.               |
| K101626  | LenSx 550 Laser System      | LenSx Lasers, Inc. (Alcon) |

#### DEVICE DESCRIPTION

The predicate LensAR Laser System is an ophthalmic surgical laser that has been cleared by the Agency for use in anterior capsulotomy and laser phaco fragmentation in cataract surgery performed individually or consecutively during the same surgery under K 120214 (LensAR Laser System - fs 3D).

The current LLS-fs 3D uses the same laser and the same beam guidance system to deliver laser pulses to the eye as the predicate LensAR device cleared via 510(k) K120214. Also, the patient interface device (PID), controlled force docking mechanism and moveable

{1}------------------------------------------------

optical head to dock the laser to the stationary patient are unchanged from that described in 510(k) K120214. The Indication for Use is now expanded to include creation of the incisions for entry to the eye in cataract surgery.

The LLS-fs 3D biometric system, which measures and constructs a three dimensional model of the optical surfaces within the eye, is unchanged from the predicate device except for software modifications to allow the system to analyze the shape and position of the peripheral cornea.

### STATEMENT OF INTENDED USE

The LensAR Laser System - fs 3D (LLS-fs 3D) is intended for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, laser phacofragmentation, and the creation of single-planc and multi-plane cuts/incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure.

## TECHNOLOGICAL CHARACTERISTICS COMPARISON

The femtosecond laser system, including pulse energy control and monitoring, used in the current LLS-fs 3D is the same as that used in the predicate device cleared in K120214. The primary difference between the current LensAR Laser System - fs 3D device and the predicate device is the addition of software for the indication of single-plane and multiplane cuts/incisions in the cornea for cataract surgery.

In the predicate device, the biometric system measured the shape and position of the central cornea for use in the ray tracing necessary to correctly place laser incisions within the crystalline lens. In the current device, corneal measurements are also used to generate custom shot patterns for the corneal incisions.

| 510(k) Number | Clearance Date | Device Description                                                                                                                                       |
|---------------|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| K120214       | 06/08/2012     | LensAR Laser System - fs 3D (LLS-fs 3D)<br>for anterior capsulotomy and laser phacofragmentation                                                         |
| K101626       | 10/18/2010     | LenSx Laser System<br>for anterior capsulotomy, phacofragmentation, and<br>creation of single-plane and multi-plane arc cuts/<br>incisions in the cornea |

- The activities used to evaluate the LensAR Laser System fs 3D (LLS-fs 3D) and . the information and reports provided in this 510(k) submission do not identify any new issues of safety or effectiveness. The optical radiation hazard analysis confirms the continuing ocular safety and the equivalence to the predicate device detailed in 510(k) K120214.

{2}------------------------------------------------

- The LLS-fs 3D laser technology and mechanism of laser-tissue interaction are . unchanged from that of the femtosecond laser cleared under K120214.
- The indication for use statement for anterior capsulotomy and laser . phacofragmentation for the LLS-fs 3D is the same as that of the predicate devices detailed in the table above and the indication for use statement for incisions of the cornea in cataract surgery is the same as the LenSx laser (K101626).
- The differences between the modified LLS-fs 3D and the predicate devices are . insignificant and do not affect the safety or effectiveness of the device.

### BRIEF SUMMARY OF PERFORMANCE TEST RESULTS

The performance data supporting substantial equivalence of the LensAR Laser System fs 3D to the predicate LensAR device is summarized as follows:

- An analysis of the optical radiation hazard to non-target tissue demonstrated that . the current LLS-fs 3D femtosecond laser, biometric system scanning diode light source, and patient eye illumination (light emitting diodes) are eye safe under all normal operating and known fault conditions.
- Evaluation of the accuracy and reproducibility of the locations and geometry of laser . vs. manual planar corneal cuts/incisions showed the mean incision length for the laser incision was statistically significantly closer to the target length than was the case for the manual CCIs. In addition, the variance of the angles of the entrance and exit planar incisions relative to the corneal surface showed that the laser incisions had statistically significantly lower variance for these geometry parameters compared to the manual incisions.
- Evaluation of the effect of the laser vs. manual incisions at the corneal periphery on ● endothelial cells of ex vivo porcine eyes showed that the laser verthed resultery on statistically smaller percentage losses compared to that of the manual issuition. method when the exit of the incision was normal to the surface but not significantly different when the exit incision geometry was at 45° to the surface.
- Evaluation of the incision seal integrity and wound structure after the laser vs. manual . incision for cataract surgery showed there was no difference in susceptiblity in. ma leakage between the two types of incisions. Overall, the testing showed that the manual and laser methods are statistically equivalent in sealability but that the laser method produces more consistent wound geometry.
- A hazard analysis of all potential hazards to the patient, surgeon and other system . operators was performed to consider all changes between the current LLS-fs 3D and predicate LLS-fs 3D device. The hazard analysis demonstrates that all potential hazards have acceptable levels of probability/severity characteristics.

{3}------------------------------------------------

#### DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles a human figure embracing or supporting another, represented by flowing lines.

December 3, 2012

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002

LensAR. Inc. c/o Ms. Shirley K. McGarvey Regulatory Consultant 2800 Discovery Drive, Suite 100 Orlando, FL 32826

Re: K122829

Trade/Device Name: LensAR Laser System - fs 3D (LLS-fs 3D) Regulation Number: 21 CFR 886.4390 Regulation Name: Ophthalmic Laser Regulatory Class: II Product Code: HQC Dated: September 14, 2012 Received: September 17, 2012

Dear Ms. McGarvey:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{4}------------------------------------------------

Page 2 - Ms. Shirley K. McGarvey

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHQffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely vours.

**Kesia Y. Alexander**

for Victor Krauthamer, Ph.D. Acting Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health

{5}------------------------------------------------

## Indications for Use Statement

K 122829 510(k) Number (if known):

Device Name:

LensAR Laser System - fs 3D (LLS-fs 3D)

Indications for Use:

The LensAR Laser System - fs 3D (LLS-fs 3D) is intended for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, laser phacofragmentation, and the creation of single-plane and multi-plane cuts/incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure.

Prescription Use: X AND/OR (Part 21 CFR 301 Subpart D)

Over-the-Counter Use: (Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Daryl Kauper, M.A.

(Division Sign-Off) Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices

510(k) Number K.122829

---

**Source:** [https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/HQC/K122829](https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/HQC/K122829)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com